Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 167

1.

Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence.

Postma MJ, Baltussen RM, Heijnen ML, de Berg LT, Jager JC.

Drugs Aging. 2000 Sep;17(3):217-27. Review.

PMID:
11043820
[PubMed - indexed for MEDLINE]
2.

Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence.

Postma MJ, Jansema P, van Genugten ML, Heijnen ML, Jager JC, de Jong-van den Berg LT.

Drugs. 2002;62(7):1013-24. Review.

PMID:
11985488
[PubMed - indexed for MEDLINE]
3.

Economic evaluation of influenza vaccination. Assessment for The Netherlands.

Postma MJ, Bos JM, van Gennep M, Jager JC, Baltussen R, Sprenger MJ.

Pharmacoeconomics. 1999;16 Suppl 1:33-40. Review.

PMID:
10623374
[PubMed - indexed for MEDLINE]
4.

Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands.

Postma MJ, Heijnen ML, Beutels P, Jager JC.

Expert Rev Vaccines. 2003 Aug;2(4):477-82.

PMID:
14711333
[PubMed - indexed for MEDLINE]
5.

Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization.

Mullooly JP, Bennett MD, Hornbrook MC, Barker WH, Williams WW, Patriarca PA, Rhodes PH.

Ann Intern Med. 1994 Dec 15;121(12):947-52.

PMID:
7978721
[PubMed - indexed for MEDLINE]
6.

Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands.

Postma MJ, Heijnen ML, Jager JC.

Pharmacoeconomics. 2001;19(2):215-22.

PMID:
11284385
[PubMed - indexed for MEDLINE]
7.

Antiviral agents for influenza: a comparison of cost-effectiveness data.

Lynd LD, Goeree R, O'Brien BJ.

Pharmacoeconomics. 2005;23(11):1083-106. Review.

PMID:
16277546
[PubMed - indexed for MEDLINE]
8.

Cost-benefit evaluation of routine influenza immunisation in people 65-74 years of age.

Allsup S, Gosney M, Haycox A, Regan M.

Health Technol Assess. 2003;7(24):iii-x, 1-65.

PMID:
14499051
[PubMed - indexed for MEDLINE]
Free Article
9.

Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.

Rothberg MB, Rose DN.

Am J Med. 2005 Jan;118(1):68-77.

PMID:
15639212
[PubMed - indexed for MEDLINE]
10.

[Influenza vaccination in the elderly population in Mexico: economic considerations].

Gutiérrez JP, Bertozzi SM.

Salud Publica Mex. 2005 May-Jun;47(3):234-9. Spanish.

PMID:
16104466
[PubMed - indexed for MEDLINE]
11.

Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.

Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K.

Health Technol Assess. 2003;7(35):iii-iv, xi-xiii, 1-170. Review.

PMID:
14609480
[PubMed - indexed for MEDLINE]
Free Article
12.

[Pharmaco-economics of anti-influenza vaccinations].

Jahnz-Rózyk K.

Pol Merkur Lekarski. 2003 Jun;14(84):679-81. Review. Polish.

PMID:
14524303
[PubMed - indexed for MEDLINE]
13.

Cost-benefit evaluation of influenza vaccination in the elderly in the Italian region of Liguria.

Gasparini R, Lucioni C, Lai P, Maggioni P, Sticchi L, Durando P, Morelli P, Comino I, Calderisi S, Crovari P.

Vaccine. 2002 Dec 20;20 Suppl 5:B50-4.

PMID:
12477420
[PubMed - indexed for MEDLINE]
14.

[Cost-effectiveness of influenza vaccination The Netherlands].

Reinders A, Postma MJ, Govaert TM, Sprenger MJ.

Ned Tijdschr Geneeskd. 1997 Jan 11;141(2):93-7. Dutch.

PMID:
9036354
[PubMed - indexed for MEDLINE]
15.

Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis.

Lugnér AK, van Boven M, de Vries R, Postma MJ, Wallinga J.

BMJ. 2012 Jul 12;345:e4445. doi: 10.1136/bmj.e4445.

PMID:
22791791
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

[Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost effectiveness analysis].

Postma MJ, Heijnen ML, Beutels P, Jager JC.

Ned Tijdschr Geneeskd. 2002 May 4;146(18):855-9. Dutch.

PMID:
12038224
[PubMed - indexed for MEDLINE]
17.

Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children.

Luce BR, Zangwill KM, Palmer CS, Mendelman PM, Yan L, Wolff MC, Cho I, Marcy SM, Iacuzio D, Belshe RB.

Pediatrics. 2001 Aug;108(2):E24.

PMID:
11483834
[PubMed - indexed for MEDLINE]
18.

The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia.

Newall AT, Scuffham PA, Kelly H, Harsley S, Macintyre CR.

Vaccine. 2008 Apr 16;26(17):2142-53. doi: 10.1016/j.vaccine.2008.01.050. Epub 2008 Feb 20.

PMID:
18343537
[PubMed - indexed for MEDLINE]
19.

The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.

Aballéa S, Chancellor J, Martin M, Wutzler P, Carrat F, Gasparini R, Toniolo-Neto J, Drummond M, Weinstein M.

Value Health. 2007 Mar-Apr;10(2):98-116.

PMID:
17391419
[PubMed - indexed for MEDLINE]
20.

Further evidence for favorable cost-effectiveness of elderly influenza vaccination.

Postma MJ, Baltussen RP, Palache AM, Wilschut JC.

Expert Rev Pharmacoecon Outcomes Res. 2006 Apr;6(2):215-27. doi: 10.1586/14737167.6.2.215.

PMID:
20528557
[PubMed]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk